ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion
15,55 USD
+6,04 %+0,89
21. Dec, 02:00:00 Uhr,
Nasdaq
Kommentare 106
Summer.76,
24.05.2023 16:46 Uhr
0
https://www.globenewswire.com/news-release/2023/05/24/2675357/0/en/ClearPoint-Neuro-and-UCB-Enter-License-Agreement-for-Gene-Therapy-Drug-Delivery.html
Summer.76,
11.05.2023 22:11 Uhr
0
ClearPoint Neuro Reports First Quarter 2023 Results
https://ir.clearpointneuro.com/news-events/press-releases/detail/1090/clearpoint-neuro-reports-first-quarter-2023-results
Biologics & Drug Delivery growing +24%; Company Reaffirms 2023 Revenue Forecast
Summer.76,
19.04.2023 6:06 Uhr
0
https://www.globenewswire.com/news-release/2023/04/18/2649556/0/en/ClearPoint-Neuro-Announces-Agreement-with-NE-Scientific-to-Integrate-Gene-Therapy-Infusion-Coverage-Tool-into-ClearPoint-Maestro-Brain-Model.html
Summer.76,
28.03.2023 22:24 Uhr
0
https://www.globenewswire.com/news-release/2023/03/28/2636196/0/en/ClearPoint-Neuro-Announces-Exclusive-Multi-Year-Licensing-Agreement-with-UCSF-for-Innovative-Intra-Cerebral-Cellular-Delivery-Platform.html
Summer.76,
01.03.2023 22:06 Uhr
0
https://ir.clearpointneuro.com/news-events/press-releases/detail/1082/clearpoint-neuro-reports-fourth-quarter-and-full-year-2022
Summer.76,
11.01.2023 15:17 Uhr
0
https://www.globenewswire.com/news-release/2023/01/11/2587014/25687/en/ClearPoint-Neuro-Reports-Fourth-Quarter-and-Full-Year-2022-Preliminary-Revenue-Results-and-Guidance-for-Full-Year-2023-Revenue.html
Vancouver,
11.01.2023 6:46 Uhr
0
=00=
Summer.76,
12.12.2022 17:20 Uhr
0
https://www.globenewswire.com/news-release/2022/12/12/2571981/0/en/ClearPoint-Neuro-Announces-First-Patient-Enrolled-in-Glioblastoma-Trial-Using-ClearPoint-Prism-Neuro-Laser-Therapy-System-at-Sk%C3%A5ne-University-Hospital-in-Sweden.html
Summer.76,
09.11.2022 5:40 Uhr
1
ClearPoint Neuro GAAP EPS of -$0.15, revenue of $5.1M
https://seekingalpha.com/news/3904123-clearpoint-neuro-gaap-eps-of-0_15-revenue-of-5_1m
• ClearPoint Neuro press release (NASDAQ:CLPT): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M.
• CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M.
• Cash and short-term investments totaled $40.5M as of Sept 30, 2022.
• CLPT said three new products were cleared by FDA in the quarter and are in the process of being deployed in limited market releases before the end of the year.
• "We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions." - President and CEO Joe Burnett
Summer.76,
09.11.2022 5:40 Uhr
0
ClearPoint Neuro Reports Third Quarter 2022 Results
https://www.globenewswire.com/news-release/2022/11/08/2551424/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2022-Results.html
Company Reaffirms 2022 Revenue Forecast
Summer.76,
23.09.2022 12:13 Uhr
0
https://www.globenewswire.com/news-release/2022/09/23/2521573/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Prism-Neuro-Laser-Therapy-System.html
Summer.76,
20.09.2022 6:27 Uhr
0
https://www.globenewswire.com/news-release/2022/09/19/2518720/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-Software-Version-2-1.html
Summer.76,
10.08.2022 5:52 Uhr
0
ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model
https://www.globenewswire.com/news-release/2022/08/09/2495317/25687/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Maestro-Brain-Model.html
Summer.76,
10.08.2022 5:52 Uhr
0
ClearPoint Neuro, Inc. Misses Q2 EPS by 16c
https://m.investing.com/news/clearpoint-neuro-inc-misses-q2-eps-by-16c-432SI-2868428?ampMode=1
Summer.76,
03.06.2022 5:49 Uhr
0
https://www.globenewswire.com/news-release/2022/06/02/2455609/25687/en/ClearPoint-Neuro-Announces-Receipt-of-MDSAP-Certification.html
Summer.76,
20.05.2022 15:48 Uhr
0
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
https://www.globenewswire.com/news-release/2022/05/20/2447753/0/en/ClearPoint-Neuro-Congratulates-Partner-PTC-Therapeutics-on-Receiving-Positive-CHMP-Opinion-for-Gene-Therapy-to-Treat-AADC-Deficiency.html
First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint’s SmartFlow® Cannula
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Dax Prognose | -0,40 % | |
2 | Brainchip Klassengruppe | ±0,00 % | |
3 | Lilium Aktie | -56,91 % | |
4 | AFC ENERGY Hauptdiskussion | +0,18 % | |
5 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | |
6 | Maxeon Solar Technologies Pte. Hauptdiskussion | -0,36 % | |
7 | INTEL Hauptdiskussion | +0,05 % | |
8 | Vulcan Energy Resources Hauptdiskussion | ±0,00 % | |
9 | PROSIEBENSAT1 MEDIA Hauptdiskussion | +0,10 % | |
10 | NIO INC.A S.ADR DL-,00025 Hauptdiskussion | +0,06 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Brainchip Klassengruppe | ±0,00 % | |
2 | Lilium Aktie | -56,91 % | |
3 | AFC ENERGY Hauptdiskussion | +0,18 % | |
4 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | |
5 | Maxeon Solar Technologies Pte. Hauptdiskussion | -0,36 % | |
6 | INTEL Hauptdiskussion | +0,05 % | |
7 | Vulcan Energy Resources Hauptdiskussion | ±0,00 % | |
8 | PROSIEBENSAT1 MEDIA Hauptdiskussion | +0,10 % | |
9 | NIO INC.A S.ADR DL-,00025 Hauptdiskussion | +0,06 % | |
10 | ATOS Hauptdiskussion | +4,76 % | Alle Diskussionen |